NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Sanders GD, Coeytaux R, Dolor RJ, et al. Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), and Direct Renin Inhibitors for Treating Essential Hypertension: An Update [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 Jun. (Comparative Effectiveness Reviews, No. 34.)
Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), and Direct Renin Inhibitors for Treating Essential Hypertension: An Update [Internet].
Show detailsA succinct summary of the results of this review of the comparative long-term benefits and harms of angiotensin-converting enzyme inhibitor(s) (ACEIs), angiotensin II receptor blocker(s)/antagonist(s) (ARBs), or direct renin inhibitors for adults with essential hypertension is provided in three tables. First, we give an aggregated view of the strength of evidence and brief conclusions (Table 27). Second, we further describe the nature and quality of the evidence (Table 28). Finally, we summarize the quantitative analyses of outcomes, offering an estimate of the comparative outcomes for ACEIs (Table 29).
Table 27
Summary of evidence on comparative long-term benefits and harms of ACEIs, ARBs, and direct renin inhibitors for essential hypertension.
Table 28
Quality of evidence summary table.
Table 29
GRADE balance sheet.
- Summary and Discussion - Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angio...Summary and Discussion - Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), and Direct Renin Inhibitors for Treating Essential Hypertension: An Update
Your browsing activity is empty.
Activity recording is turned off.
See more...